The United Laboratories International Holdings (HK:3933) has released an update.
The United Laboratories International Holdings Limited has announced the acceptance of their Insulin Degludec Injection by China National Medical Products Administration, marking a significant stride in diabetes treatment with their new generation long-acting basal insulin analog. The company is further developing a range of diabetes-related products, emphasizing its commitment to innovation and value creation in the biopharmaceutical industry for its shareholders.
For further insights into HK:3933 stock, check out TipRanks’ Stock Analysis page.
